A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD

Study acronym: SEC-HOPE
StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 4 → 7 locations
    • Eligibility criteria expanded, about 16 words
    • Secondary endpoints: details revised at 6 of 12 entries
  2. Study sites: 3 to 4v4
  3. Recruitment opened
    • Trial sites expanded: 0 → 3 locations
    • Start date changed from estimate of Jul 15, 2026 to Jul 8, 2026
    v3
  4. Re-verified, no change to tracked fieldsv2
  5. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Novartis
556 trials monitored
See 32 trials at risk
NASH / MASH
690 trials monitored
See 23 trials at risk
Psoriasis
593 trials monitored
See 24 trials at risk
This study aims to examine the retention rate of secukinumab in adult patients with plaque psoriasis (with or without psoriatic arthritis \[PsA\]) and metabolic dysfunction-associated steatotic liver disease (MASLD) in routine clinical practice in Spain, as well as hepatic biomarker trajectories. The study will use electronic medical record (EMR) data from multiple Spanish hospitals.
Trial Details
NCT Number NCT07683065
Lead Sponsor Novartis Pharmaceuticals
Conditions
(from sponsor)		 Plaque Psoriasis, Metabolic Dysfunction-Associated Steatotic Liver Disease
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov